Nomax Therapeutics has filed a notice of an exempt offering of securities to raise $10,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Nomax Therapeutics is raising $10,000,000.00 in new funding. Sources indicate that as part of senior management President, Max Temnik played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Nomax Therapeutics
At Nomax Therapeutics we are an international multidisciplinary team united to fight against neurodegenerative diseases. We are passionate about providing efficient, fundamental science based innovative products with no harmful side effects. Our team is comprised of specialists in mathematics, physics, chemistry, immunology, and neuropathology.
To learn more about Nomax Therapeutics, visit http://nomaxtherapeutics.com/
Contact:
Max Temnik, President
305-331-1213
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.